Konjonktiva tümörlerinde tanı ve tedavi

Benign konjonktiva tümörleri genç popülasyonda daha sık görülürken premalign-malign konjonktiva tümörleri eriskin ve yaslı popülasyonda daha sık görülmektedir. Konjonktiva tümörlerinin klinik özellikleri dikkate alınarak biyomikroskopik muayene ile ön tanı konulabilmekte ve etkin tedavi seçeneği ile basarılı sonuçlar elde edilebilmektedir. Benign ve premalign-malign konjonktiva tümörleri arasında kesin ayırım histopatolojik inceleme ile yapılmaktadır. Benign konjonktiva tümörlerinde TEB ile etkin tedavi sağlanmaktadır. Premalign-malign konjonktiva tümörlerinde geçmiste kullanılan enükleasyon ve egzenterasyon gibi agresif tedavi seçenekleri yerine günümüzde TEB'e ek olarak uygulanan kriyoterapi, alkol epitelyektomi ve topikal MMC gibi yöntemleri tercih edilmektedir. Tedavi seçimini etkileyen faktörler arasında: tümörünün benign veya premalign-malign klinik özellikleri tasıması, tümörün yerlesim yeri ve yaygınlığı (kornea, göziçi ve orbitaya invazyon olup olmaması), histopatolojik inceleme sonrası tümörün histopatolojik özellikleri, cerrahi sınırlarda tümöral hücre mevcudiyeti, diğer gözün durumu, hastanın yası, genel sağlık durumu ve hastanın tercihi yer almaktadır. Bu çalısmada, toplam 209 konjonktiva tümörü olan olgunun klinik özellikleri, uygulanan tedavi, histopatolojik sonuçları, gelisen nüks ve nüks tedavisi incelendi. Arastırmaya dahil edilen olguların 109'u kadın (%52.2), 100'ü (%47.8) erkek idi. Hastaların yas ortalaması 52.1±20.1 yıl iken ortalama izlem süresi 72.8 hafta idi. Klinik ve patolojik değerlendirme sonucunda hastaların 60'ında (%28.7) benign, 149'unda (%71.3) ise premalign-malign konjonktiva tümörü saptandı. Premalignmalign konjonktiva tümörlerinde benign konjonktiva tümörlerine göre yas ortalaması istatistiksel olarak daha yüksek idi. Benign konjonktiva tümörü olan olguların 31'i (%51.7) kadın, 29'u (%48.3) erkek idi. Benign konjonktiva tümörü olan olguların 23'ü (%38.2) nevüs, 8'i (%13.3) papillom, 4'ü (%6.7) limbal dermoid, 4'ü (%6.7) lenfanjiom, 1'i (%1.7) piyojenik granülom, 1'i (%1.7) epibulber koristom, 1'i (%1.7) psödoepitelyomatöz hiperplazi, 1'i (%1.7) kapiller hemanjiom, 13'ü (%21.6) tümör içermeyen dokular ve 4'ü (%6.7) dejenerasyon, grubunda yer almaktaydı. Konjonktiva nevüsü olan olguların yas ortalaması diğer benign konjonktiva tümörlerine göre istatistiksel anlamlı olarak daha düsük idi (21.5±14.3yıl). Papillom erkeklerde kadınlara göre daha sık görülmekteyken (%75) diğer benign konjonktiva tümörlerinde cinsiyet açısından istatistiksel olarak anlamlı bir fark görülmedi. Benign konjonktiva tümörlerinden 8 olgu (%13.3) izleme alınırken 52 olguya (%86.7) TEB veya subtotal eksizyonel biyopsi cerrahisi uygulandı. Premalign-malign konjonktiva tümörü olan olguların 78'i (%52.3) kadın ve 71'i (%47.7) erkek idi. Premalign-malign konjonktiva tümörü olan olguların 42'sinde (%28.2) K?N, 72'sinde (%48.3) YHK, 8'inde (%5.4) PEM, 15'inde (%10.1) MM, 2'sinde (%1.3) RLH ve 10'unda (%6.7) malign lenfoma mevcuttu. PEM'li toplam 8 (%5.4) olgudan 2 (%25) olguda PEM ve MM birlikte görüldü. Premalignmalign konjonktiva tümörlerinde tedavi olarak, 43 olguda (%30) TEB+Kriyo+AE, 28 olguda (%19) TEB+Kriyo, 20 olguda (%14) TEB+Kriyo+AE+MMC, 10 olguda (%7) TEB+AE, 7 olguda (%5) TEB+Kriyo+AE+AMT, 7 olguda (%5) TEB+Kriyo+Str-90, 7 olguda (%5) TEB+Kriyo+MMC, 6 olguda(%4) TEB+KriyoAE+Str-90, 6 olguda (%4) TEB+Kriyo+RT, 2 olguda (%1) TEB+Kriyo+KT, 4 olguda (%3) enükleasyon ve 3 olguda (%2) ekzenterasyon uygulandı. Histopatolojik incelemede 29 olguda (%20.3) cerrahi sınırlar pozitif, 61 olguda (%42.6) cerrahi sınırlar negatif iken 53 olguda (%37.1) cerrahi sınırlar belirtilmemis idi. Birinci nüks görülme oranı %34.3 (49/143) idi. YHK'da birinci nüks %45.8 iken MM'da %41.2 idi. K?N grubunda nüks gelismedi. Yas ilerledikçe 1. nüks gelisme ihtimali de istatistiksel anlamlı olarak artmaktaydı. Tümör büyüklüğü, cinsiyet ve tümör lokalizasyonu ile 1.nüks arasında istatistiksel olarak anlamlı bir birliktelik saptanmadı. Birinci nüks tedavisi olarak 24 olguda (%49) TEB+Kriyo+AE+MMC, 9 olguda (%18) TEB+Kriyo+AE, 8 olguda (%5) TEB+Kriyo+MMC, 2 olguda (%4) TEB+Kriyo+AE+AMT, 1 olguda (%2) TEB+AE, 3 olguda (%6) enükleasyon ve 2 olguda (%4) ekzenterasyon uygulandı. Histopatolojik incelemede 6 olguda (%12.2) cerrahi sınırlar pozitif, 18 olguda (%36.7) cerrahi sınırlar negatif iken 25 olguda (%51.1) cerrahi sınırlar belirtilmemis idi. ?kinci nüks görülme oranı %11.2 (16/143) idi. YHK'da ikinci nüks oranı %18.1 ve MM'da %11.8 olarak bulundu. Yas, tümör büyüklüğü, cinsiyet, tümör lokalizasyonu ile ikinci nüks arasında istatistiksel olarak anlamlı bir birliktelik saptanmadı. ?kinci nüks tedavisi olarak 6 olguda (%38) TEB+Kriyo+AE+MMC, 4 olguda (%25) TEB+Kriyo+AE, 4 olguda (%25) TEB+Kriyo+MMC, 1 olguda (%6) TEB+AE ve 1 olguda (%6) TEB+Kriyo+AE+AMT uygulandı. ?kinci nüks tedavi sonrası 5 olguda (%31.3) cerrahi sınırlar pozitif iken 11 olguda (%68.7) cerrahi sınırlar negatif idi. Üçüncü nüks görülme oranı %3.5 (5/143) idi. Üçüncü kez nüks eden olguların 4'ü YHK iken 1 olgu MM idi. Cerrahi sınırlarda tümöral hücre mevcudiyeti ve yas nüks açısından risk faktörü olarak bulundu. ?ki malign lenfomalı hastada sistemik tutulum ve 1 malign melanomlu hastada rejyonel lenf bezi pozitif idi. ?zlem süresince hiçbir hastada exitus gelismedi. Sonuç olarak, benign konjonktiva tümörlerinde TEB ile etkin tedavi sağlanmaktadır. Premalign-malign konjonktiva tümörlerinin tedavisinde TEB'e ek olarak uygulanan kriyoterapi, alkol epitelyektomi ve topikal MMC ile nüks oranınında azalma ve uzun dönemde basarılı sonuçlar elde edilmektedir. Yaygın malign konjonktiva tümörlerinde AMT oküler yüzey rekonstrüksiyonu açısından gereklidir. Yaygın ve göziçi invazyonu gösteren malign konjonktiva tümörlerinde enükleasyon; orbita invazyonu gösteren malign tümörlerde ise ekzenterasyon uygulanmaktadır. AbstractAlthough benign conjunctival tumors are seen more frequently in young population; premalignant-malignant conjunctival tumors are seen more frequently in adults and elderly population. Early diagnosis can be made based on biomicroscopic examination of conjunctival tumors? clinical characters and successful results can be obtained with effective treatment option. Definite discrimination, between benign and premalignant-malignant conjunctival tumors, is obtained by histopathological examination. Effective treatment for benign conjunctival tumors is obtained with total excisional biopsy (TEB). Nowadays; aggressive treatment options, such as enucleation and exenteration, which were used in the past, gave way to cryotherapy, alcohol epitheliectomy and topical mitomycin C (MMC) which are used in addition to TEB. The factors that affect treatment selection are whether the tumor has benign or premalignant-malignant clinical feature, site and extention (whether there is an invasion to the cornea or intraocular or orbita) of the tumor, histopathologic features of the tumor after the histopathologic examination, tumoral cell presence in the surgical border, situation of the other eye, age and general health state of the patient and patient?s choice. In this study, clinical features of totally 209 patients with conjunctival tumors, treatment methods employed, histopathologic results, recurrence rates and management of the recurrences were examined. 109 (52.2%) of the patients were women and 100 (47.8%) of them were men. Mean follow-up was 72.8 weeks, whereas mean age of the patients was 52.1±20.1. According to clinical and pathological assessment; 60 patients (28.7%) were diagnosed as benign conjunctival tumor and 149 patients (71.3%) were diagnosed as premalignant-malignant conjunctival tumor. Mean age of patientsts with premalignant-malignant conjunctival tumor was statistically larger than mean age of patients with benign conjunctival tumor. 31 of patients with benign conjunctival tumors were women (51.7%) and 29 of them were men (48.3%). Among the patients with benign conjunctival tumors, 23 patients (38.2%) had nevus, 8 patients (13.3%) had papilloma, 4 patients (6.7%) had limbal dermoid, 4 patients (6.7%) had lymphangioma, 1 patient (1.7%) had pyogenic granuloma, 1 patient (1.7%) had epibulbar choristoma, 1 patient (1.7%) had pseudoepitheliamatous hyperplasia, 1 patient (1.7%) had capillary hemangioma, 13 patients (21.6%) had nontumoral tissue and 4 patients (6.7%) had degeneration. Mean age of patients with conjunctival nevus was statistically lower than other benign conjunctival tumors (21.5±14.3 years). No statistically significant difference was found about sex, among other benign conjunctival tumors; whereas papilloma was seen in men more frequently than women (75%). TEB or subtotal excisional biopsy were done in 52 patients (86.7%) who have benign conjunctival tumor, whereas other 8 patients, who have benign conjunctival tumor, (13.3%) were followed up. 78 patients with premalignant-malignant conjunctival tumor (52.3%) were women and 71 patients (47.7%) were men. Among the patients with premalignantmalignant conjunctival tumor, 42 patients (28.2%) had conjunctival intraepithelial neoplasia (CIN), 72 patients (48.3%) had squamous cell carcinoma (SCC), 8 patients (5.4%) had primary acquired melanosis (PAM), 15 patients (10.1%) had malignant melanoma (MM), 2 patients (1.3%) had reactive lymphoid hyperplasia (RLH) and 10 patients (6.7%) had malignant lymphoma. PAM and MM were seen together in 2 (25%) of 8 patients (5.4%) who had PAM. In the treatment of premalignantmalignant conjunctival tumors total excisional biopsy+cryotherapy+alcohol epitheliectomy (TEB+Cryo+AE) were applied in 43 patients (%30), total excisional biopsy+cryotherapy (TEB+Cryo) were applied in 28 patients (19%), total excisional biopsy+cryotherapy+alcohol epitheliectomy+mitomycin C (TEB+Cryo+AE+MMC) were applied in 20 patients (14%), total excisional biopsy+alcohol epitheliectomy (TEB+AE) were applied in 10 patients (7%), total excisional biopsy+cryotherapy+alcohol epitheliectomy+amniotic membrane transplantation (TEB+Cryo+AE+AMT) were applied in 7 patients (5%), total excisional biopsy+cryotherapy+strontium-90 (TEB+Cryo+Str-90) were applied in 7 patients (5%), total excisional biopsy+cryotherapy+mitomycin C (TEB+Cryo+MMC) were applied in 7 patients (5%), total excisional biopsy+cryotherapy+alcohol epitheliectomy+strontium-90 (TEB+Cryo+AE+Str-90) were applied in 6 patients (4%), total excisional biopsy+cryotherapy+radiotherapy (TEB+Cryo+RT) were applied in 6 patients (4%), total excisional biopsy+cryotherapy+chemotherapy (TEB+Cryo+CT) were applied in 2 patients (1%), enucleation was applied in 4 patients (3%) and exenteration was applied in 3 patients (2%). According to histopathological examination; surgical borders were negative in 61 patients (42.6%), whereas it was positive in 29 patients (20.3%) and unknown in 53 patients (37.1%). Recurrence was noted in 34.3% (49/143) of patients. Primary recurrence was seen in 45.8% of patients with SCC and in 41.2% of patients with MM. However; there has not been any recurrence in CIN group. Primary recurrence probability significantly increased with increasing age in statistical analysis. No statistically significant relationship was found between tumor size, sex and tumor localization with primary recurrence. As a treatment for recurrence, TEB+Cryo+AE+MMC were applied in 24 patients (49%), TEB+Cryo+AE were applied in 9 patients (18%), TEB+Cryo+MMC were applied in 8 patients (5%), TEB+Cryo+AE+AMT were applied in 2 patients (4%), TEB+AE were applied in 1 patients (2%), enucleation was applied in 3 patients (6%) and exenteration was applied in 2 patients (4%). Surgical borders were negative in 18 patients (36.7%) whereas it was positive in 6 patients (12.2%) and unknown in 25 patients (51.1%). Second recurrence was seen in 11.2% (16/143) of patients. Second recurrence was found in 18.1% of patients with SCC and in 11.8% of patients with MM. No statistically significant relationship was found between age, tumor size, sex, tumor localization with second recurrence. As second recurrence treatment, TEB+Cryo+AE+MMC were applied in 6 patients (38%), TEB+Cryo+AE were applied in 4 patients (25%), TEB+Cryo+MMC were applied in 4 patients (25%), TEB+AE were applied in 1 patients (6%) and TEB+Cryo+AE+AMT were applied in 1 patients (6%). Surgical borders were negative in 11 patients (68.7%) whereas it was positive in 5 patients (31.3%) after the secondary recurrence treatment. Third recurrence was observed in 3.5% (5/143) of patients. 1 patient had MM whereas 4 patient had SCC among the cases who had third recurrence. Tumoral positivity at the surgical borders and patients age were found a risk factor for recurrence. Systemical involvement was positive in 2 patients with malignant lymphoma and regional lymph node was positive in 1 patient with malignant melanoma. During the follow-up period there has not been any cases who died. Successful results in long term and decrease in recurrence ratio can be obtained with cryotherapy, alcohol epitheliectomy, topical MMC in addition to TEB in premalignant-malignant conjunctival tumor treatment. AMT is essential for ocular surface reconstruction in widespread malignant conjunctival tumors. Enucleation is used for malignant conjunctival tumors that exhibit widespread and intraocular invasion; exenteration is used for malignant tumors that exhibit orbital invasion.

Grantor dc:publisher

Ankara Üniversitesi Tıp Fakültesi Göz Hastalıkları Anabilim Dalı

Authors dc:creator

• ALİEVA HASANOVA, Şenay (Yazar)
• GÜNDÜZ, Kaan (Tez Danışmanı)

• TIP

Language dc:language.iso

tr

Handle dc:identifier.uri

http://hdl.handle.net/20.500.12575/22209

OAI record oai:identifier

https://dspace.ankara.edu.tr/server/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Adspace.ankara.edu.tr%3A20.500.12575%2F22209